Inicio/Acciones/AURA

AURA

USD

Aura Biosciences Inc. Common Stock

$6.630-0.460 (-6.488%)

Precio en Tiempo Real

Healthcare

Biotecnología

Estados Unidos

Gráfico de Precios

Loading Chart...

Métricas Clave

Métricas de Mercado

Fundamentos de la Empresa

Estadísticas de Negociación

Métricas de Mercado

Apertura

$7.090

Máximo

$7.120

Mínimo

$6.615

Volumen

0.28M

Fundamentos de la Empresa

Capitalización de Mercado

411.1M

Industria

Biotecnología

País

United States

Estadísticas de Negociación

Volumen Promedio

0.30M

Bolsa

NGM

Moneda

USD

Rango de 52 Semanas

Mínimo $4.345Actual $6.630Máximo $12.378

Noticias Relacionadas

28 may 2025 · 10:33

Analyst Upgrades

HC Wainwright & Co. Assumes Aura Biosciences at Buy, Announces Price Target of $22

HC Wainwright & Co. analyst Andres Maldonado assumes Aura Biosciences with a Buy rating and announces Price Target of $22.

HC Wainwright & Co. Assumes Aura Biosciences at Buy, Announces Price Target of $22

23 may 2025 · 13:22

Analyst Upgrades

JMP Securities Reiterates Market Outperform on Aura Biosciences, Maintains $19 Price Target

JMP Securities analyst Jonathan Wolleben reiterates Aura Biosciences with a Market Outperform and maintains $19 price target.

JMP Securities Reiterates Market Outperform on Aura Biosciences, Maintains $19 Price Target

15 may 2025 · 13:32

GlobeNewswire

Aura Biosciences Announces Pricing of Public Offering of Common Stock and Warrants

BOSTON, May 15, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. ("Aura") (NASDAQ:AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today

Aura Biosciences Announces Pricing of Public Offering of Common Stock and Warrants

15 may 2025 · 10:10

GlobeNewswire

Aura Biosciences Announces Proposed Public Offering of Common Stock and Warrants

15 may 2025 · 10:01

GlobeNewswire

Aura Biosciences Reports First Quarter 2025 Financial Results and Business Highlights

First Patient Enrolled in Multi-Dose Phase 1b/2 Trial of Bel-sar in Non-Muscle-Invasive Bladder Cancer (NMIBC); Initial Data at 3 Months Expected by Year-End 2025 Strengthened Leadership Team with the Appointment of